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Abstract
Purpose Patients suffering from cardiovascular autonomic failure often develop neurogenic supine hypertension (nSH), i.e., 
high blood pressure (BP) in the supine position, which falls in the upright position owing to impaired autonomic regula-
tion. A committee was formed to reach consensus among experts on the definition and diagnosis of nSH in the context of 
cardiovascular autonomic failure.
Methods As a first and preparatory step, a systematic search of PubMed-indexed literature on nSH up to January 2017 
was performed. Available evidence derived from this search was discussed in a consensus expert round table meeting in 
Innsbruck on February 16, 2017. Statements originating from this meeting were further discussed by representatives of the 
American Autonomic Society and the European Federation of Autonomic Societies and are summarized in the document 
presented here. The final version received the endorsement of the European Academy of Neurology and the European Society 
of Hypertension.
Results In patients with neurogenic orthostatic hypotension, nSH is defined as systolic BP ≥ 140 mmHg and/or diastolic 
BP ≥ 90 mmHg, measured after at least 5 min of rest in the supine position. Three severity degrees are recommended: mild, 
moderate and severe. nSH may also be present during nocturnal sleep, with reduced-dipping, non-dipping or rising nocturnal 
BP profiles with respect to mean daytime BP values. Home BP monitoring and 24-h-ambulatory BP monitoring provide 
relevant information for a customized clinical management.
Conclusions The establishment of expert-based criteria to define nSH should standardize diagnosis and allow a better under-
standing of its epidemiology, prognosis and, ultimately, treatment.
Keywords Neurogenic supine hypertension · Nocturnal hypertension · Neurogenic orthostatic hypotension · ABPM · 
Autonomic failure
Introduction
Primary cardiovascular autonomic failure develops in the 
context of inherited and sporadic neurodegenerative diseases 
affecting the autonomic nervous system. Secondary causes 
 * Gregor K. Wenning 
 gregor.wenning@i-med.ac.at
Extended author information available on the last page of the article
356 Clinical Autonomic Research (2018) 28:355–362
1 3
of cardiovascular autonomic failure include amyloidosis and 
metabolic or immune-mediated diseases inducing autonomic 
neuropathy [1].
The main feature of cardiovascular autonomic failure is 
neurogenic orthostatic hypotension (nOH), defined in 2011 
as a sustained reduction of systolic blood pressure (BP) 
of ≥ 20 mmHg (≥ 30 mmHg in patients with supine hyper-
tension) or diastolic BP  of ≥  10 mmHg within 3 min of 
standing or head-up tilt of at least 60° [2]. About one-half 
of the patients with nOH develop neurogenic supine hyper-
tension (nSH), which can be severe and last several hours 
during sleep [3]. nSH is distinct from essential hypertension, 
since most patients with nSH are normotensive while seated 
and may be severely hypotensive while standing [4–6].
As yet, no consensus criteria have been established for 
the diagnosis of nSH, limiting current understanding of its 
epidemiology, prognostic significance and the development 
of appropriate management strategies.
To address this shortcoming, a round table discussion 
with participants from the European Federation of Auto-
nomic Societies (EFAS) and from the American Autonomic 
Society (AAS) was convened in Innsbruck on February 16, 
2017 to establish clinical criteria for the diagnosis of nSH in 
the context of cardiovascular autonomic failure.
Discussion points and statements originating from this 
meeting were subsequently examined and reviewed by rep-
resentatives of both societies and are summarized in the 
document presented here. The final version was endorsed 
by the European Academy of Neurology (EAN) and by the 
European Society of Hypertension (ESH).
Definitions
Supine hypertension
In patients with proven nOH, nSH is defined as systolic BP 
of ≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg, meas-
ured after at least 5 min of rest in the supine position.
We propose the following ranges to define the severity of 
nSH in autonomic failure:
• Mild nSH: systolic BP values of 140–159 mmHg or dias-
tolic BP values of 90–99 mmHg.
• Moderate nSH: systolic BP values of 160–179 mmHg or 
diastolic BP values of 100–109 mmHg.
• Severe nSH: systolic BP values of ≥ 180 mmHg or dias-
tolic BP values of   ≥ 110 mmHg.
Nocturnal hypertension
Patients with cardiovascular autonomic failure frequently 
show nSH also during sleep, i.e. nocturnal hypertension, 
with loss of the physiological nocturnal BP fall at night of ≥ 
10% while supine and asleep (dipping). Two main pathologi-
cal nocturnal BP profiles are distinguished:
• Reduced-dipping: characterized by a mean nocturnal BP 
reduction of < 10% with respect to mean daytime BP values.
• Non-dipping or rising: when the mean BP does not 
decrease or even increases during the night with respect 
to daytime [7, 8].
Additional aspects are important for an appropriate inter-
pretation of 24 h-ambulatory BP monitoring (24 h-ABPM) 
in patients with cardiovascular autonomic failure and are 
discussed in the section Diagnostic work-up.
Clinical features
Neurogenic supine hypertension is mostly asymptomatic or 
induces only non-specific complaints, such as headache. The 
main, most clinically relevant and immediate consequence of 
nSH is an exacerbation of pressure natriuresis during sleep, 
causing nocturia, sleep disturbances, volume depletion over-
night and worsening of nOH in the morning [9, 10].
nSH could potentially result in hypertensive emergen-
cies, with similar complications as in the general population, 
i.e. cerebral hemorrhage, ischemic stroke, acute pulmonary 
edema and myocardial infarction [11], although the overall 
occurrence of these clinical events has not been systemati-
cally investigated in cardiovascular autonomic failure. Acute 
cardiovascular complications associated with nSH have been 
reported, but mainly in patients also receiving anti-hypoten-
sive drugs [12, 13], which are known to induce or exacerbate 
nSH (Fig. 1).
The long-term effects of cardiovascular autonomic fail-
ure have been studied in patients with Parkinson’s disease 
(PD) and multiple system atrophy (MSA). Current evidence 
suggests that early-onset cardiovascular autonomic failure is 
associated with a poor prognosis [14–20], development of car-
diovascular [21–23], kidney [24] and cerebrovascular [25–30] 
disease, as well as cognitive impairment [26, 27, 31–36]. 
Similarly, a higher prevalence of left ventricular hypertro-
phy, nephropathy and vascular and cerebrovascular disease 
has been reported in diabetic patients with secondary cardio-
vascular autonomic failure compared to those without [37].
At present, it is uncertain how much of the increase in 
risk is related to the underlying disease causing autonomic 
failure and how much is directly related to the abnormality 
in BP regulation. It is also unclear whether nOH or nSH 
represents the actual negative prognostic factor in patients 
with cardiovascular autonomic failure—or whether it is the 
BP volatility induced by the combination of both [38].
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Epidemiology
Keeping in mind the limitations due to inconsistences in 
the diagnostic criteria, nSH has been reported in 34–46% 
of patients with PD and 37% of patients with MSA [3, 39]. 
The frequency rates of nSH increase to 50% in parkinsonian 
patients with nOH, supporting the assumption of an etiologi-
cal association between nOH and nSH [3, 39–42]. Loss of 
nocturnal BP dipping has been frequently reported in PD 
(48%) and MSA patients (up to 75%) [43–46].
The prevalence of nSH in pure autonomic failure (PAF) 
ranges from 48 to 70% [24, 47]. An abnormal, non-dipping, 
nocturnal BP profile has been described in up to 86% of 
patients with PAF [48].
To date, no studies have addressed the epidemiology of 
nSH in diabetes, but a significant association has been reported 
Fig. 1  Nocturnal blood pressure 
(BP) profiles at 24 h-ambulatory 
BP monitoring a Physiological 
nocturnal dipping profile (mean 
nocturnal BP falls by ≥ 10% 
with respect to  daytime BP), b 
reduced-dipping profile (mean 
nocturnal BP falls by < 10% 
with respect to daytime BP), c 
rising profile (mean nocturnal 
BP increases with respect to 
daytime BP), in a patient with 
cardiovascular autonomic 
failure. Note severe hypotension 
occurring in the early morning. 
HR Heart rate. The blue area 
indicates the pulse pressure, the 
green line indicates the mean 
BP. Adapted from Fanciulli 
et al. [44], with permission of 
Springer SBM. This image is 
excluded from the creative com-
mons license 
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between the presence of nOH and rising nocturnal BP profiles 
both in patients with type 1 and type 2 diabetes mellitus [49, 
50].
The prevalence of nSH in genetic and acquired amyloi-
dosis, as well as in other kinds of autonomic neuropathies 
is unknown. Clinically, patients with acquired amyloidosis 
(AL) and nOH often present with relatively low supine BP 
measurements which may be related to cardiovascular amy-
loid deposition.
Pathophysiology
Anti-hypotensive drugs used for the treatment of nOH may 
unmask or exacerbate nSH, thereby posing a management 
challenge. However, nSH can also develop in the absence of 
anti-hypotensive treatment, which reflects the likelihood that 
multiple factors contribute to nSH, including impairment 
of the afferent, central and efferent pathways of the arterial 
baroreflex arch, disruption of the renin–angiotensin–aldos-
terone axis and denervation supersensitivity at the level of 
the vascular adrenoceptors due to impaired sympathetic 
transmission [6, 41, 51–53].
Noradrenaline release from intact post-ganglionic sym-
pathetic fibers in the setting of severe baroreflex impairment 
drives nSH in MSA, which is characterized in most cases by 
severe preganglionic sympathetic denervation, with sparing 
of the post-ganglionic sympathetic fibers to the heart and 
blood vessels [53].
In contrast, mechanisms independent of the sympathetic 
autonomic nervous system are considered to contribute 
to the development of nSH in autonomic disorders with 
post-ganglionic sympathetic denervation and very low cir-
culating noradrenaline levels, such as in PAF [53]. Para-
doxically increased angiotensin II and aldosterone receptor 
signaling in the setting of decreased activity of the systemic 
renin–angiotensin–aldosterone system has been implicated 
[51, 54]. In contrast, an impairment in nitric oxide-mediated 
vasodilation has not been observed in patients with nSH due 
to primary cardiovascular autonomic failure [55].
Diagnostic work‑up
All patients newly diagnosed with nOH should be screened 
for nSH at the time of diagnosis and at regular intervals 
afterwards, especially if they begin treatment with anti-
hypotensive agents, increase their dosage, report multiple 
episodes of nocturia per night or develop ankle edema.
Office screening should be performed by measuring 
supine BP as soon as the patient assumes the supine posi-
tion and then again after the patient has been resting supine 
for at least 5 min. This can be combined with a standing test, 
by having the patient stand immobile to avoid engaging the 
muscle pumps in the lower limbs, or with a tilt table exami-
nation. A tilt table examination may be preferred in patients 
unable to stand for several minutes.
It should be noted that the criteria outlined here to define 
nSH only apply for patients with proven nOH: if present, 
both conditions are usually verified during the same test. 
Exceptions to this rule may be due to the fact that nOH 
and nSH could manifest with different degrees of severity 
according to the time of the day, intravascular volume status 
and timing of the administration of anti-hypotensive drugs. 
Anti-hypotensive drugs may succeed in raising the standing 
BP and improving symptoms, but exacerbate nSH.
A diagnosis of nSH should be also made independently 
from seated BP values, which may vary from hypertensive 
values to normo- or hypotensive values in patients with car-
diovascular autonomic failure.
In addition to office BP screening, home BP recordings 
performed by patients themselves are recommended to 
gather further insights into circadian BP control. Although 
no protocol for home BP self-monitoring has been validated 
in patients with cardiovascular autonomic failure, we rec-
ommend that the BP be recorded three times per day (early 
morning, after lunch, at bedtime) in the supine, seated and 
standing position for 1 week at first diagnostic work-up. The 
same home BP protocol should be repeated after the initia-
tion or adaptation of any treatment for nOH or nSH in order 
to monitor therapeutic effects and to detect potential side 
effects. Comparison of supine and seated BP values during 
the daytime is particularly valuable for choosing therapeutic 
strategies: patients with nSH may show normal BP values 
while seated, hence benefitting from a simple non-pharma-
cological approach such as avoiding the supine position dur-
ing daytime.
If office BP screening or home BP recordings suggest 
nSH, a 24 h-ABPM is recommended to ascertain the pres-
ence of nocturnal hypertension and document absolute BP 
levels reached overnight. 24 h-ABPM may also provide 
information on the severity of nOH during daily activity 
or after meals (“post-prandial hypotension” [56]), thus sup-
porting customization of the therapeutic management [57].
Additional considerations are required when interpreting 
24 h-ABPM data of patients with cardiovascular autonomic 
failure:
– Several activities of daily life may cause severe drops 
in BP, which may be captured in the 24-h recordings. 
For an accurate interpretation of the 24 h-ABPM data, 
patients should be instructed to compile an activity diary 
on the examination day in which they report the times 
of medication intake (especially anti-hypotensive and 
anti-hypertensive agents), meals, physical activities and 
times of getting out of bed at night (for example, to use 
the bathroom).
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– Extreme drops in BP during daytime will reduce mean 
BP during the daytime, thereby resulting in an overes-
timation of the percentage of nocturnal BP rise. Con-
versely, nocturnal standing or bathroom visits may 
induce nocturnal BP falls, which may result in an under-
estimation of the BP rise overnight. For these reasons, 
both the percentage of nocturnal BP rise, as well as the 
absolute overnight BP values should be considered when 
diagnosing and tailoring treatment strategies for nSH. 
Whereas non-dipping and rising nocturnal patterns have 
been associated with long-term end-organ damage, abso-
lute BP values reached while supine may be more rel-
evant for the development of hypertensive emergencies.
– Sleeping with the bed 12° head-up tilted (or higher, if 
tolerated) creates an overnight gravitational stress and 
is an effective non-pharmacological strategy to manage 
nOH [58]. Sleeping with the whole bed tilted can miti-
gate the severity of nocturnal nSH by inducing venous 
pooling below the level of the heart throughout the night. 
Sleeping with only the head of the bed raised appears to 
be less effective in lowering night-time BP. Close atten-
tion should be therefore paid to the angle of the bed when 
interpreting the 24 h-ABPM data.
– Patients with cardiovascular autonomic failure, especially 
in the setting of PD and MSA, may suffer from sleep 
fragmentation or sleep disordered breathing, both of 
which have been associated with development of hyper-
tension [59–61]. If sleep disordered breathing is sus-
pected at clinical history taking or based on 24 h-ABPM 
data (for example, by documenting multiple nocturnal 
hypertensive peaks), a targeted diagnostic work-up is 
indicated.
– Nocturnal BP profiles may change over the short term 
with repeated 24  h-ABPM in 10–35% patients with 
essential hypertension [62, 63]. Reproducibility of the 
24 h-ABPM readings in patients with cardiovascular 
autonomic failure remains to be investigated. This may 
be important as BP can fluctuate on a day-to-day basis 
due to multiple factors.
Finally, if a nocturnal BP rise is documented in a patient 
not known to suffer from any autonomic disorder, screening 
for nOH may be indicated. Similarly, if a patient is found to 
have elevated BP while supine—for example, in a hospital 
or acute care setting—they should also have the BP meas-
ured seated and, if the systolic difference exceeds 10 mmHg, 
standing as well. Otherwise, nSH might be mistaken for 
essential hypertension, and if treatment decisions are based 
on supine BP values alone, medications could potentially 
worsen unrecognized nOH.
Perspectives
Current epidemiological data are not sufficient to define cut-
offs for nSH based on its impact on end-organ damage or 
mortality. For this reason, the criteria proposed here for the 
diagnosis of nSH in the context of cardiovascular autonomic 
failure are based on the criteria for the diagnosis of essential 
hypertension and interpretation of 24 h-ABPM recordings 
in the general population [7, 8]. There are several reasons 
supporting this strategy: first, to facilitate the use of these 
cut-off values in clinical practice; second, to apply severity 
degrees of nSH as a tool for customizing treatment and grade 
adverse events in future interventional clinical trials for 
nOH; third, to generate data which can be compared across 
other epidemiological cohorts, such as essential hyperten-
sion. These definitions of nSH should ultimately lead to a 
better understanding of the prognostic outcome and stratifi-
cation of the risk of adverse events.
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